Z
Zenshine Pharmaceuticals
Small molecule therapeutics for cancer and viral infections
About Zenshine Pharmaceuticals
Zenshine Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2018 by industry veterans Jinfu Yang and Xiaolin Alan Hao. The company is headquartered in Nanjing, China, with research operations in Hangzhou and a clinical and business development presence in the San Francisco Bay Area. Zenshine focuses on developing small molecule therapeutics for cancer, viral infections, and inflammation.
The company's strategy involves targeting key biological pathways to interrupt virus replication, block tumor growth directly, and bolster anti-tumor immune responses. Zenshine has built a pipeline of drug candidates, including ZX-101A, a next-generation PI3Kδ/γ inhibitor for hematologic malignancies and solid tumors, and ZX-4081, a PI3Kγ inhibitor for solid tumors. Another key asset is ZX-7101A (Seloxavir Marboxil), a single-dose oral antiviral for influenza A and B. In July 2025, Zenshine received regulatory approval in China to market Seloxavir Marboxil.
Zenshine has secured significant funding through several rounds, including a Series A in December 2020, a Series A+ of over $30 million in May 2021, and subsequent Series B and C rounds in 2023. These funds are being used to advance its pipeline through global clinical trials. The company has received multiple IND (Investigational New Drug) approvals from both the U.S. FDA and China's NMPA, and has progressed several candidates into Phase 1, 2, and 3 clinical trials.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Oct 2023 | $14M | $344M | Kunlun Capital · Zhonghui Investment · Jiaxing Zhonghui Shengping Venture Capital · Hangzhou Saizhichuang Yunqiqi Venture Capital | ↗ |
| SERIES B✓Equity / VC | Mar 2023 | $14M | $248M | Ennovation Ventures · Nanjing Yang Zi State-Owned Investment Group · Hankang Capital · Nanjing Jiangbei New District Science and Technology Investment Group | ↗ |
Growth signals
Latest recorded traffic for Zenshine Pharmaceuticals is 440 monthly website visits, up 238.5% over the last three months. Zenshine Pharmaceuticals's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Zenshine Pharmaceuticals in the Hangzhou ecosystem
The Zenshine Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
- JCJiuyou Capital
- NCNanjing Zijin Technology Venture Capital
Indaco Capital- JCJiakang Venture Capital
Matrix Partners China- LCLYZZ Capital
State Development & Investment Corporation (SDIC)- EVEnnovation Ventures
Nanjing Yang Zi State-Owned Investment Group
Hankang Capital- NGNanjing Jiangbei New District Science and Technology Investment Group
- CYCybernaut
Series B and later5 investors entered at this stage
Kunlun Capital- ZIZhonghui Investment
- JCJiaxing Zhonghui Shengping Venture Capital
- HCHangzhou Saizhichuang Yunqiqi Venture Capital
- JUJumpcan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zenshine Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zenshine Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










